A 35-year-old man from Delhi presents with a 3-month history of productive cough, fever, and night sweats. He was diagnosed with pulmonary tuberculosis 8 months ago and completed 4 months of standard first-line anti-TB therapy (HRZE). Despite adherence, sputum smear microscopy remains positive. Chest X-ray shows persistent cavitary lesions in the right upper lobe. Sputum culture and drug susceptibility testing (DST) reveal resistance to both isoniazid and rifampicin. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: MDR-TB (Multidrug-Resistant Tuberculosis) **Key Point:** Resistance to both isoniazid (INH) and rifampicin (RIF) defines MDR-TB, regardless of resistance to other drugs. This patient meets the definition after treatment failure on standard first-line therapy. ### Why This Patient Has MDR-TB - Persistent positive sputum smear after 4 months of standard therapy = **treatment failure** - DST confirms resistance to **both INH and RIF** = MDR-TB by definition - Risk factors: inadequate drug absorption, poor adherence (though patient claims compliance), or primary drug-resistant strain ### Management of MDR-TB: WHO/RNTCP Guidelines **High-Yield:** MDR-TB requires a **longer, more intensive regimen** with second-line drugs: | Component | Standard First-Line | MDR-TB Regimen | |-----------|-------------------|----------------| | **Duration** | 6 months | 20 months (intensive: 6 mo, continuation: 14 mo) | | **Core drugs** | HRZE | Fluoroquinolone (levofloxacin/moxifloxacin) + Injectable (amikacin/kanamycin) + Bedaquiline | | **Additional** | — | Linezolid, clofazimine, ethionamide (if needed) | ### Correct Regimen Components 1. **Fluoroquinolone** (e.g., levofloxacin 750 mg daily) - Bactericidal, good lung penetration - Backbone of MDR-TB therapy 2. **Injectable agent** (e.g., amikacin 15 mg/kg IV/IM daily for 6 months) - Second-line injectable; monitor renal function and audiometry 3. **Bedaquiline** (400 mg daily × 2 weeks, then 200 mg 3× weekly) - **New TB drug**, ATP synthase inhibitor - Significantly improves cure rates in MDR-TB 4. **Additional agents** as needed: linezolid, clofazimine, ethionamide **Clinical Pearl:** Bedaquiline has revolutionized MDR-TB outcomes, reducing treatment duration from 24 to 20 months and improving cure rates from ~50% to ~70%. ### Why Other Options Are Incorrect - **Continuing HRZE:** Patient is already resistant to both INH and RIF; continuing will not work and risks further resistance acquisition. - **Adding ETH + PZA only:** These are first-line agents; the patient is already resistant to INH/RIF, so adding more first-line drugs is ineffective. - **Surgical resection:** Reserved for **XDR-TB with localized disease** or MDR-TB with **extensive cavitary disease unresponsive to medical therapy** after ≥6 months of appropriate MDR regimen. Not first-line here. **Mnemonic:** **MDR = More Drugs Required** — Fluoroquinolone + Injectable + Bedaquiline (FIB) is the modern backbone.